Table 2.
Cohorts From Symptomatic Patients Tested for Respiratory Viral Targets That Included Adenovirus, HCoV-229E, HCoV-HKU1, HCoV-NL63, HCoV-OC43, HMPV, Enterovirus/Rhinovirus, and HPIV1–4 in Addition to Chlamydia pneumoniae and Mycoplasma pneumoniae
| Cohort 1 (Samples From Symptomatic Patients Tested Clinically and Were Negative for SARS-CoV-2/Influenza/RSV) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| October 2020 | November 2020 | December 2020 | January 2021 | February 2021 | March 2021 | April 2021 | May 2021 | July 2021 | August 2021 | September 2021 | October 2021 | Total | |
| Total tested | 16 | 37 | 37 | 36 | 37 | 37 | 48 | 46 | 294 | ||||
| Total positives | 3 | 2 | 2 | 6 | 2 | 3 | 1 | 6 | 25 | ||||
| %Positivity | 18.8 | 5.4 | 5.4 | 16.7 | 5.4 | 8.1 | 2.1 | 13.0 | 8.5 | ||||
| Targets detected | Enterovirus/rhinovirus (3) | Enterovirus/ rhinovirus (1) | Enterovirus/ rhinovirus (1) | Enterovirus/ rhinovirus (4) | Enterovirus/rhinovirus (2) | Enterovirus/rhinovirus (2) | Enterovirus/ rhinovirus (1) | Enterovirus/ rhinovirus (3) | 17 | ||||
| Adenovirus (1) | Adenovirus (1) | Adenovirus (1) | Adenovirus (3) | 6 | |||||||||
| HPIV2 (1) | 1 | ||||||||||||
| HCoV-OC43 (1) | 1 | ||||||||||||
| Cohort 2 (Samples From Symptomatic Patients Tested Clinically and Were Positive for SARS-CoV-2) | |||||||||||||
| Total tested | 1 | 12 | 33 | 3 | 35 | 4 | 91 | 179 | |||||
| Fully vaccinated | 71 | ||||||||||||
| Unvaccinated | 108 | ||||||||||||
Abbreviations: HCoV, human coronaviruses; HMPV, human metapneumovirus; HPIV, human parainfluenza virus; RSV, respiratory syncytial virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.